Manufacturing hurdles grow as next-gen protein therapeutics gain traction

Cytiva's sponsored piece highlights growing interest in next-generation protein-based drugs such as antibody-drug conjugates, multispecific antibodies, fragments and synthetic peptides.

These modalities are seeing increasing regulatory approvals and many are in clinical trials, offering potential gains in efficacy, selectivity and reduced toxicity compared with traditional antibodies.

Their structural complexity creates new hurdles for process development and manufacturing, requiring novel upstream and downstream strategies.

For high-potency ADCs, manufacturers must implement safety upgrades to protect operators from toxic payload-linker chemicals and control exposure during production.